IL92161A0 - Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon - Google Patents

Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon

Info

Publication number
IL92161A0
IL92161A0 IL92161A IL9216189A IL92161A0 IL 92161 A0 IL92161 A0 IL 92161A0 IL 92161 A IL92161 A IL 92161A IL 9216189 A IL9216189 A IL 9216189A IL 92161 A0 IL92161 A0 IL 92161A0
Authority
IL
Israel
Prior art keywords
treatment
combination
liquid nitrogen
recombinant dna
human alpha
Prior art date
Application number
IL92161A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL92161A0 publication Critical patent/IL92161A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL92161A 1988-11-01 1989-10-30 Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon IL92161A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/265,612 US4959210A (en) 1988-11-01 1988-11-01 Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon

Publications (1)

Publication Number Publication Date
IL92161A0 true IL92161A0 (en) 1990-07-12

Family

ID=23011173

Family Applications (1)

Application Number Title Priority Date Filing Date
IL92161A IL92161A0 (en) 1988-11-01 1989-10-30 Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon

Country Status (12)

Country Link
US (1) US4959210A (xx)
EP (2) EP0369632A1 (xx)
JP (1) JPH03503766A (xx)
KR (1) KR900701309A (xx)
AU (1) AU636312B2 (xx)
CA (1) CA2001884A1 (xx)
DK (1) DK79591A (xx)
IL (1) IL92161A0 (xx)
MY (1) MY106603A (xx)
PH (1) PH26680A (xx)
WO (1) WO1990004977A2 (xx)
ZA (1) ZA898234B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5165921A (en) * 1989-01-23 1992-11-24 National Geno Sciences, Inc. Method for treating condyloma acuminatum with interferon
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
PT99837A (pt) * 1990-12-21 1992-12-31 Schering Corp Processo para a preparacao de composicoes farmaceuticas contendo interferao alfa e metodo para administracao de interferao alfa por inalacao oral para tratar asma e doencas pulmonares proliferativas nao malignas
US6309662B1 (en) 1999-09-23 2001-10-30 Janet Buchanan Use of anti-inflammatory drugs for treatment of dermatological conditions
US7436227B2 (en) * 2003-05-02 2008-10-14 Silicon Laboratories Inc. Dual loop architecture useful for a programmable clock source and clock multiplier applications
CA2553040A1 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US20110218241A1 (en) * 2010-03-06 2011-09-08 Cacao Bio-Technologies, Llc Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts
WO2018178215A1 (en) 2017-03-31 2018-10-04 Accanis Biotech F&E Gmbh & Co Kg Prevention and treatment of non-melanoma skin cancer (nmsc)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503035B1 (en) * 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
US4286690A (en) * 1979-03-05 1981-09-01 Commercial Management Corporation Escape device
JPS59175416A (ja) * 1983-03-25 1984-10-04 Sunstar Inc 皮膚および粘膜の角化異常治療用外用剤
CA1321347C (en) * 1986-11-10 1993-08-17 David C. Munch Human leukocyte interferon composition and skin treatment

Also Published As

Publication number Publication date
MY106603A (en) 1995-06-30
CA2001884A1 (en) 1990-05-01
PH26680A (en) 1992-09-15
AU636312B2 (en) 1993-04-29
KR900701309A (ko) 1990-12-01
JPH03503766A (ja) 1991-08-22
DK79591D0 (da) 1991-04-30
EP0369632A1 (en) 1990-05-23
US4959210A (en) 1990-09-25
DK79591A (da) 1991-06-14
WO1990004977A2 (en) 1990-05-17
EP0445145A1 (en) 1991-09-11
AU4524689A (en) 1990-05-28
ZA898234B (en) 1990-07-25
WO1990004977A3 (en) 1990-06-28

Similar Documents

Publication Publication Date Title
ZA935697B (en) Peptides capable of inhibiting the activity of hiv protease their preparation and their therapeutic use
EP0349235A3 (en) Niacin-containing composition and its therapeutic use
ZA949104B (en) Recombinant viruses and their use in gene therapy
IL90489A0 (en) Recombinant coccidiosis vaccines and their preparation
HUP9802324A2 (hu) Ribavirin és alfa-interferon felhasználása hepatitis C kezelésére
EP0349594A4 (en) Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
EP0291970A3 (en) Homogeneous addition copolymers of ethylene and cycloolefin monomers
AR243240A1 (es) Procedimiento para preparar una proteina con actividad de factor estimulador de colonia y acido nucleico que comprende una secuencia nucleotidica capaz de modificarla.
IL111682A0 (en) Recombinant viruses and their use in gene therapy
IL92161A0 (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
GB2184653B (en) Dementia-improving and therapeutic agents
NZ214702A (en) Using interferon in treatments and pharmaceutical compositions
ZA895010B (en) Treatment of genital warts with a combination of podophyllin and recombinant dna human alpha interferion
ZA89202B (en) Recombinant human interleukin-1 alpha polypeptides
JPS6425796A (en) Insulin bonding peptide and its use
PH24632A (en) Tin diiododeuteroporphyrin and therapeutic use thereof
EP0267684A3 (en) Human leukocyte interferon composition and skin treatment
ZA925514B (en) Expression of enzymatically active recombinant human actylcholinesterase and use thereof
EP0238893A3 (en) Recombinant parvovirus ra-1 products and methods of use thereof
ZA9010337B (en) Fibroblast growth factor for use in the prevention and treatment of viral infections
CS397389A3 (en) Mobile chair for lifting and transfer of invalids
IE893500L (en) Treating genital warts with liquid nitrogen and human alpha¹interferon
SG130694G (en) Peptide fragments of hiv and their use in vaccines and diagnosis
GB2174600B (en) Induction of ovulation in mares
EP0415420A3 (en) Device preventing the occlusion of blood vessels in the shoulder and upper arm area during sleep